Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Antiviral Res. 2021 Mar 13;189:105062. doi: 10.1016/j.antiviral.2021.105062

Fig. 1.

Fig. 1.

Isavuconazole inhibits HCMV replication in a dose-dependent manner. (A) Plaque reduction assays were performed in HFF infected with the indicated HCMV strains and treated with different doses (from 0.1 to 25 μM) of ICZ. Cell viability curve in the presence of ICZ was obtained by MTT assays at 120 h. (B) Dose-dependent inhibition of virus progeny production by ICZ in HCMV-infected HFFs as determined by virus yield reduction assays. (C) Dose-dependent inhibition of the replication of HCMV strains resistant to currently available viral DNA polymerase inhibitors. In all panels, graphs report the mean ± SD of n ≥ 3 independent experiments in duplicate.